Fintech PR
Two Leading Patent Professionals & Intellectual Property Strategists Join Ocean Tomo, a part of J.S. Held
JERICHO, N.Y., Oct. 23, 2024 /PRNewswire/ — Global consulting firm J.S. Held, proudly celebrating 50 transformative years, joins Ocean Tomo in welcoming David Kennedy and Larry Tedesco to the intellectual property (IP) practice.
David Kennedy, CPA, is an expert in intellectual property valuation and negotiating the economics of patent sales and licensing agreements. He has been acknowledged as one of the World’s Leading IP Strategists by Intellectual Asset Management (IAM) for each of the last 11 years.
Mr. Kennedy has bought and sold patent portfolios, negotiated license agreements in commercial transactions, and helped clients establish royalty rates for individual patents and large portfolios of implementation and standard essential patents. Additionally, he has provided forensic consulting services in litigation matters and has testified as an expert witness in numerous matters involving patents, copyrights, and trade secrets covering a wide variety of technologies and technical benefits. Mr. Kennedy has testified as a patent licensing and reasonable royalty expert in ICC International Arbitration proceedings and federal courts – including opining on royalty rates for standard essential patents, implementation patents, and US and worldwide portfolio rates.
His intellectual property experience includes:
- 35 years as a CPA, auditor, and accounting consultant for corporations, financial institutions, government agencies, and law firms performing audits, litigation support, IP and asset valuation, IP management, and forensic accounting services
- Serving as the primary negotiator or advisor in over 200 IP-related negotiations as both an owner of IP or on behalf of companies, universities, and inventors, including patent sales, license agreements, and cross-license agreements
- Review and analysis of thousands of patent license agreements to determine effective royalty rates and evaluate specific aspects of the license negotiation process to determine comparable licenses for litigation and negotiation purposes
Mr. Kennedy’s professional experience started over 35 years ago as a CPA for Coopers & Lybrand (now PWC). His experience includes investing in and raising venture capital for intellectual property-based companies and negotiating the economics of patent sales. He has also purchased patent portfolios and implemented licensing programs as an owner and manager of the patents and on behalf of investor groups, inventors, and corporations, including the determination of appropriate royalty rates in the marketplace.
Larry Tedesco, CVA, CLP, MAFF, is an intellectual property valuation, licensing, and damages expert. He is acknowledged as one of the World’s Leading IP Strategists and Patent Professionals by Intellectual Asset Management (IAM). Mr. Tedesco has spent a large portion of his career developing, managing, valuing, and licensing intellectual property as both an operator and a consultant. He has provided multiple levels of damages evaluations for both plaintiffs and defendants in a wide range of IP disputes. He is a Certified Valuation Analyst (CVA), a Certified Licensing Professional (CLP), and a Master Analyst in Financial Forensics (MAFF).
Mr. Tedesco has provided forensic and expert consulting services in litigation matters regarding patent royalty structures and modeling, lost profits, reasonable royalties, unjust enrichment, trade secrets, and other forms of economic damages related to complex commercial litigation, IP licensing, and valuation. Mr. Tedesco has reviewed and analyzed thousands of license agreements. He has determined FRAND royalty rates for Standard Essential Patents in a variety of technologies including wireless telecommunications, Wi-Fi, and audio/video.
His experience includes:
- More than 20 years of IP development, valuation, monetization, and enforcement
- Negotiating over 200 IP transactions
- Review and analysis of thousands of license agreements
- Damages evaluation, including lost profits, reasonable royalty, unjust enrichment, and other forms of economic damages
- Assisting clients with the determination of FRAND/RAND royalty rates for standard essential patents.
As an operator, Mr. Tedesco has significant experience monetizing intellectual property in a wide variety of industries, including telecommunications, medical devices, software development, electronics, manufacturing, and augmented reality. He has held senior-level management positions where he obtained extensive experience developing patent assets in addition to designing and implementing IP licensing programs. Mr. Tedesco has negotiated more than 200 IP transactions and managed the licensing program to an industry-leading essential Ethernet patent portfolio.
These two stalwart experts join a multidisciplinary team of multidimensional experts – accountants, financiers, scientists, lawyers, and engineers. Together, the team provides a leading array of financial and technical services related to intangible assets. Built upon more than three decades of experience valuing IP in the most rigorous of venues: state, federal, and international courts, Ocean Tomo financial, market, and technical experts, with an understanding of the contributory value of patented inventions, know-how, brands, and copyrights that permeate every business.
“We have known and worked with David and Larry for decades. We are grateful to have them now as part of the Ocean Tomo team, enhancing our scope of experience and ability to provide a full-service solution on IP matters,” shared Ocean Tomo co-founder and Senior Managing Director James E. Malackowski, CPA, CLP.
Ocean Tomo financial testimony professionals have industry-leading experience across all types of disputes and are particularly skilled in the determination of damages in matters involving IP. The firm’s IP experts have decades of litigation analysis experience, benefiting clients when they evaluate complex financial data, qualitative facts, supporting testimony, and damages-related case law. Ocean Tomo experts are routinely qualified in U.S. District Courts, U.S. Bankruptcy Courts, U.S. Tax Court, U.S. Court of Federal Claims, state courts, the U.S. Patent and Trademark Office Patent Trial and Appeal Board, international courts, and arbitration tribunals on questions relating to IP economics. Ocean Tomo experts are known for a “teaching” – as opposed to “telling” – approach of testimony. Rather than only providing a judge or jury with an opinion, experts communicate the key facts and relevant theories in a clear and logical manner.
The Ocean Tomo team specializes in understanding and leveraging intellectual property with offerings that include financial expert testimony, IP valuation, strategy consulting, business intelligence, technical support, investment advisory, innovation management consulting, and transaction brokerage.
As a part of J.S. Held, Ocean Tomo works alongside more than 1,500 professionals globally and assists clients – corporations, law firms, insurers, governments, and institutional investors – on complex technical, scientific, and financial matters across all assets and value at risk.
David Kennedy and Larry Tedesco are now part of the dedicated and entrepreneurial experts who help transform J.S. Held. Explore our story, and celebrate this momentous milestone, our 50 & Forward celebration, with us at jsheld.com.
About J.S. Held
J.S. Held is a global consulting firm that combines technical, scientific, financial, and strategic expertise to advise clients seeking to realize value and mitigate risk. Our professionals serve as trusted advisors to organizations facing high stakes matters demanding urgent attention, staunch integrity, proven experience, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.
More than 1,500 professionals serve organizations across six continents, including 81% of the Global 200 Law Firms, 70% of the Forbes Top 20 Insurance Companies (85% of the NAIC top 50 Property & Casualty Insurers), and 65% of the Fortune 100 Companies.
About Ocean Tomo
Ocean Tomo, a part of J.S. Held, provides Expert Opinion, Management Consulting, Advisory, and Specialty Services focused on matters involving intellectual property (IP) and other intangible assets. Practice offerings address economic damage calculations and testimony; business licensing strategy and contract interpretation; patent-focused business intelligence; portfolio development strategy; litigation support; trade secret reasonable measures; asset and business valuation; strategy and risk management consulting; merger and acquisition advisory; debt and equity private placement; and IP brokerage.
J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held, its affiliates and subsidiaries are not law firms and do not provide legal advice. Securities offered through PM Securities, LLC, d/b/a Phoenix IB, a part of J.S. Held, member FINRA/ SIPC or Ocean Tomo Investment Group, LLC, a part of J.S. Held, member FINRA/ SIPC. All rights reserved.
Media Contact
Kristi L. Stathis, J.S. Held, +1 786 833 4864, [email protected], JSHeld.com
Photo – https://mma.prnewswire.com/media/2537981/Ocean_Tomo_JS_Held.jpg
Logo – https://mma.prnewswire.com/media/1774904/Ocean_Tomo_JS_Held_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/two-leading-patent-professionals–intellectual-property-strategists-join-ocean-tomo-a-part-of-js-held-302284610.html
MUMBAI, India, Oct. 23, 2024 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30th September 2024.
|
Consolidated Financial Highlights |
||||||
|
(in ₹ Cr. or as stated) |
||||||
|
Particulars |
Q2FY25 |
Q2FY24 |
YoY |
H1FY25 |
H1FY24 |
YoY |
|
Revenue from Operations |
2,242 |
1,911 |
17 % |
4,193 |
3,660 |
15 % |
|
CDMO |
1,324 |
1,068 |
24 % |
2,381 |
1,967 |
21 % |
|
CHG |
643 |
589 |
9 % |
1,274 |
1,206 |
6 % |
|
ICH |
277 |
256 |
8 % |
541 |
495 |
9 % |
|
EBITDA |
403 |
315 |
28 % |
627 |
485 |
29 % |
|
EBITDA Margin |
18 % |
16 % |
– |
15 % |
13 % |
– |
|
Share of Net Profit of Associates |
17 |
19 |
(10) % |
40 |
33 |
18 % |
|
PAT |
23 |
5 |
350 % |
(66) |
(94) |
NM |
|
PAT Margin |
1 % |
0 % |
– |
(2) % |
(3) % |
– |
Key Highlights for Q2FY25
- Revenue from Operations grew by 17% YoY, primarily driven by robust growth in CDMO business
- EBITDA grew by 28% YoY with EBITDA margin of 18%, a YoY improvement of about 150bps, driven by operating leverage, cost optimization initiatives and superior revenue mix
- Released our FY2024 Sustainability Report. The report follows GRI standards and is aligned with SASSB and UNGC frameworks. It also highlights our commitment to reduce our GHG1 emissions in-line with SBTi’s2 1.5o decarbonization pathway
Nandini Piramal, Chairperson, Piramal Pharma Limited said, “We continue our momentum of delivering healthy revenue growth accompanied by YoY EBITDA margin expansion. This has been primarily driven by consistent growth in our CDMO business which has witnessed a good pick-up in innovation related work and on-patent commercial revenues. To sustain this growth momentum and to capitalize on rising demand for sterile fill-finish capabilities, we have announced a US$80Mn expansion plan at our Lexington facility which is expected to get complete by end FY27. In our CHG business, we are witnessing steady volume growth in Inhalation Anesthesia products in the US and Emerging Markets. In our ICH business, we continue to see a robust growth in our power brands and e-commerce sales.
During the quarter, we released our Sustainability Report for FY24 under the theme, ‘Building Resilience for a Sustainable Tomorrow’, highlighting our progress on the sustainability initiatives.
Over the long term, we remain committed to achieving our financial goals of US$2 bn revenue with 25% EBITDA margin and 1x net debt / EBITDA by FY30.”
1. Green House Gas; 2. Science Based Target initiative
|
Key Business Highlights for Q2 and H1 FY25 |
|
Contract Development and Manufacturing Organization (CDMO): – Market outlook – Biotech funding improved over previous years but remains uneven across months. Regulatory changes and supply chain diversification driving increase in customer enquiries and visits, but decision making by customers remains delayed – Targeted Business Development efforts resulting in steady inflow of new orders – YoY improvement in demand in our generic API business – Operating leverage and cost optimization initiatives yielding continued YoY improvement in EBITDA margins – Maintained our quality track record with receipt of EIR for our PPDS facility (India) with Zero Form – 483 observations and NAI designation – Customer led US$80Mn expansion planed in Lexington to more than double our capacity to capture rising demand for Sterile Fill-Finish capabilities
Complex Hospital Generics (CHG): – Good volume growth in inhalation anesthesia portfolio in the US and emerging markets – Capacity expansion at Dahej and Digwal underway to capture growth opportunity in the RoW markets – Investing in portfolio expansion – Building portfolio of Differentiated and Specialty products to drive long term profitable growth – Working on multiple cost optimization and productivity enhancement initiatives in the areas of sourcing, manufacturing, distribution, and operational excellence to maintain our healthy EBITDA margin in this business
India Consumer Healthcare (ICH): – Added 9 new products and 13 new SKUs to our portfolio during H1FY25 – Continue to invest in media and trade spends to drive growth in Power Brands. Power Brands grew by 18% YoY in Q2 and H1 FY25 and contributed to 48% of ICH sales – Growth in i-range adversely impacted due to regulator mandated price reductions – E-commerce grew by over 30% YoY in Q2 and H1 FY25. Focus on improving the profitability of this channel through pricing, mix and investment optimization – Plan to widen our reach – Transition from a Pharmacy-dominant to an Omni-channel consumer healthcare company. Establish winning NPDs from online channel to offline, with general trade and modern trade ready SKUs
|
|
Consolidated Profit and Loss Statement |
||||||||
|
(in ₹ Cr. or as stated) |
||||||||
|
Particulars |
Quarterly |
Half Yearly |
||||||
|
Q2FY25 |
Q2FY24 |
YoY |
Q1FY25 |
QoQ Change |
H1FY25 |
H1FY24 |
YoY |
|
|
Revenue from Operations |
2,242 |
1,911 |
17 % |
1,951 |
15 % |
4,193 |
3,660 |
15 % |
|
Other Income |
61 |
49 |
24 % |
20 |
213 % |
81 |
88 |
(8) % |
|
Total Income |
2,303 |
1,961 |
17 % |
1,971 |
17 % |
4,274 |
3,748 |
14 % |
|
Material Cost |
796 |
638 |
25 % |
674 |
18 % |
1,471 |
1,264 |
16 % |
|
Employee Expenses |
560 |
516 |
8 % |
580 |
(3) % |
1,139 |
1,012 |
13 % |
|
Other Expenses |
544 |
492 |
11 % |
493 |
10 % |
1,037 |
986 |
5 % |
|
EBITDA |
403 |
315 |
28 % |
224 |
80 % |
627 |
485 |
29 % |
|
Interest Expenses |
108 |
110 |
(2) % |
107 |
1 % |
215 |
228 |
(6) % |
|
Depreciation |
192 |
185 |
4 % |
185 |
4 % |
377 |
358 |
5 % |
|
Share of Net Profit of Associates |
17 |
19 |
(10) % |
22 |
(23) % |
40 |
33 |
18 % |
|
Profit Before Tax |
120 |
40 |
204 % |
(45) |
NM |
75 |
(68) |
NM |
|
Tax |
98 |
35 |
182 % |
44 |
124 % |
141 |
26 |
442 % |
|
Net Profit after Tax |
23 |
5 |
350 % |
(89) |
NM |
(66) |
(94) |
NM |
|
Exceptional item |
– |
– |
– |
– |
– |
– |
– |
– |
|
Net Profit after Tax after Exceptional Item |
23 |
5 |
350 % |
(89) |
NM |
(66) |
(94) |
NM |
|
Consolidated Balance Sheet |
||
|
(in ₹ Cr. or as stated) |
||
|
Key Balance Sheet Items |
As at |
|
|
30-Sep-24 |
31-Mar-24 |
|
|
Total Equity |
7,907 |
7,911 |
|
Net Debt |
4,235 |
3,932 |
|
Total |
12,143 |
11,843 |
|
Net Fixed Assets |
9,096 |
9,106 |
|
Tangible Assets |
4,298 |
4,250 |
|
Intangible Assets including goodwill |
3,669 |
3,740 |
|
CWIP (including IAUD*) |
1,130 |
1,116 |
|
Net Working Capital |
2,651 |
2,339 |
|
Other Assets# |
396 |
398 |
|
Total Assets |
12,143 |
11,843 |
|
*IAUD – Intangible Assets Under Development; # Other Assets include Investments and Deferred Tax Assets (Net) |
||
Q2FY25/H1FY25 Earnings Conference Call
Piramal Pharma Limited will be hosting a conference call for investors / analysts on 24th October 2024 from 5:00 PM to 5:45 PM (IST) to discuss its Q2 and H1 FY25 Results.
The dial-in details for the call are as under:
|
Event |
Location & Time |
Telephone Number |
|
Conference call on |
India – 05:00 PM IST |
+91 22 6280 1461 / +91 22 7115 8320 (Primary Number) |
|
1 800 120 1221 (Toll free number) |
||
|
USA – 07:30 AM (Eastern Time – New York) |
Toll free number 18667462133 |
|
|
UK – 12:30 PM (London Time) |
Toll free number 08081011573 |
|
|
Singapore – 07:30 PM (Singapore Time) |
Toll free number 8001012045 |
|
|
Hong Kong – 07:30 PM (Hong Kong Time) |
Toll free number 800964448 |
|
|
Express Join with Diamond Pass™ |
Please use this link for prior registration to reduce wait time at the time of joining the call – Click Here |
|
About Piramal Pharma Limited:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.
For more information, visit: Piramal Pharma | LinkedIn
* Includes one facility via PPL’s minority investment in Yapan Bio
Logo: https://mma.prnewswire.com/media/2538752/Piramal_Pharma_Limited_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-results-for-q2-and-h1-fy25-302284959.html
NEW YORK, Oct. 23, 2024 /PRNewswire/ — EquiLend, the global leader in technology, data, and analytics solutions for the securities finance industry, today announced the appointment of Rich Grossi as its new Chief Executive Officer. Grossi brings a wealth of experience in fintech, operational excellence, and strategic leadership, positioning EquiLend to accelerate its growth and innovation within the securities finance market.
“I’m honored to join EquiLend at such a pivotal time for both the company and the securities finance industry,” Grossi stated. “EquiLend’s unique technology platform and differentiated suite of solutions enable a level of transparency, automation, and efficiency that is unmatched in the market. I look forward to working closely with the team to build on this foundation and help clients gain even more value from our solutions.”
“We are thrilled to welcome Rich as EquiLend’s new CEO,” said Ryan Harper, General Partner at WCAS, EquiLend’s largest shareholder. “Rich’s deep expertise in trading, treasury, and risk management software, along with his successful track record of leading and growing companies in the fintech space, make him the ideal leader to take EquiLend into its next phase of growth.”
Most recently, Grossi served as the Chief Executive Officer of ION Corporates, a suite of trading, risk management, and workflow automation solutions. During his tenure, he led ION to become the leader in treasury and commodity management, consolidating several acquisitions, innovating the product suite, and delivering growth for the business across their expansive customer base of corporations, banks, and financial institutions.
Prior to leading ION Corporates, Grossi held various leadership positions at OpenLink, where he served as Chief Executive Officer, Chief Financial Officer, Chief Product and Technology Officer, and Executive Vice President of Global Operations. His seamless transition across these leadership roles throughout his career highlights his unique blend of product, operational, and financial experience, along with his customer-centric philosophy—all of which will be key assets as EquiLend continues to expand its market presence.
“We couldn’t be more excited to have Rich join the EquiLend team,” said Paul Nigrelli, Chief Financial Officer at EquiLend. “His deep product expertise and customer-focused mindset will be transformative for EquiLend as we drive further automation of the securities finance industry. Rich’s experience and leadership will enable us to build on our more than 20-year legacy of delivering cutting-edge solutions that redefine market efficiency and connectivity.”
With the backing of WCAS and its strategic shareholders—including Bank of America, BlackRock, Goldman Sachs, Morgan Stanley, National Bank of Canada, State Street, and UBS—EquiLend is positioned to accelerate its growth and enhance its suite of technology solutions. Grossi’s appointment signals EquiLend’s commitment to scaling its business and delivering even greater value to its clients.
For more information about EquiLend and its comprehensive suite of financial technology solutions, please visit www.equilend.com.
About EquiLend
EquiLend is a global financial technology firm offering Trading, Post-Trade, Data & Analytics, RegTech and Platform Solutions for the securities finance industry. With offices in North America, EMEA and Asia-Pacific, EquiLend operates across various jurisdictions worldwide, adhering to the highest regulatory standards. The company is committed to excellence and innovation and is consistently recognized for its contributions to the industry. EquiLend is Great Place to Work Certified™ in the U.S., UK, Ireland and India and has been awarded Americas and EMEA Data Provider of the Year and Regulatory Solution of the Year in the Securities Finance Times Industry Excellence Awards 2024. For more information, please visit www.equilend.com
Press Contacts
For EquiLend: [email protected]
Logo – https://mma.prnewswire.com/media/1060364/EquiLend_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/equilend-announces-appointment-of-new-chief-executive-officer-302284059.html
Finfare Connect, a market-leading rewards platform empowering businesses to engage and retain customers through personalized offers, has announced an innovative collaboration with ZBD, a leading payments company at the forefront of digital economies.
Finfare Connect is a part of Finfare Inc., a thriving fintech company with offices in Irvine, California and London.
Through this strategic alliance, Finfare will provide ZBD users with access to affiliate, card-linked, and instant cashback offers, enabling them to earn Bitcoin through everyday purchases, above and beyond those already earned via the ZBD app.
Beginning today, ZBD users will have the option to link their payment card or multiple payment accounts to start automatically earning rewards while shopping online or at in-person stores. Card linking involves connecting a single payment card, while account linking occurs when a user connects multiple bank accounts to earn highly customized rewards.
In terms of rewards, ZBD users who sign up for the program will have access to offers from thousands of well-known brands such as Nike, Adidas, Asics, Crocs, Tommy Hilfiger, Urban Outfitters, Cole Haan, Steve Madden; and popular retailers such as Nordstrom, Brookstone and Best Buy, among many others.
ZBD’s innovative app immerses users in a world of games and apps, allowing them to earn Bitcoin while enjoying diverse entertainment experiences.
Now, US-based ZBD users will be able to seamlessly earn Bitcoin through their everyday purchases simply by linking their payment accounts via the ZBD app. Then, they will automatically earn Bitcoin whenever they purchase an item that’s promoted by FinFare.
“We are thrilled to launch this exciting offering with ZBD,” said Alan Zrado, Executive Vice President, Finfare Connect. “Through this alliance, we are enhancing the way ZBD users engage with digital payments, offering them unparalleled opportunities to earn Bitcoin through their everyday transactions. This partnership also underscores our commitment to empowering businesses by providing their customers with compelling, customized, and valued rewards.”
“We are excited to join forces with Finfare Connect to give ZBD users greater value by giving them more ways to easily earn Bitcoin rewards,” said Ben Cousens, Chief Strategy Officer of ZBD. “By combining Finfare Connect’s expertise in personalized offers with ZBD’s cutting-edge payments technology, we are providing our users with a great way to earn Bitcoin by shopping as they normally would anyway.”
The post ZBD and Finfare partner to offer gamers cash rewards for their everyday purchases! appeared first on HIPTHER Alerts.
-
Fintech2 days agoFintech Pulse: Your Daily Industry Brief – Market Moves, Platform Innovations, and Strategic Shifts
-
Fintech PR6 days agoEQT Exeter Real Estate Income Trust acquires 200,000 square-foot industrial property in Seattle for over $80M, bringing total capital deployed to approximately $390M since inception
-
Fintech PR5 days agoKroll Liquidators Secured Multi-Million Dollar Settlement Between Emergent Fidelity Technologies and FTX Estate Approved by US Bankruptcy Court
-
Fintech PR5 days ago
Deepening International Friendship and Cooperation! The 6th China-CEEC Local Leaders’ Meeting Held in Yantai
-
Fintech PR5 days agoRace to the Top: Bybit Adds $1 Million to WSOT 2024 Prize Pool – Final Days to Register!
-
Fintech PR17 hours agoH&M Foundation: Global Change Award 2025 launched – with a mission to accelerate innovation for a net-zero textile industry by 2050
-
Fintech PR1 day agoAnkura Taps Industry Veteran Regina Lee to Lead Risk, Forensics & Compliance Business Globally
-
Fintech PR2 days agoEscher Releases the Future of Posts 2024 Report: Digital Transformation and E-commerce Dominate Industry Trends